CN111334507B - Sheep Lrh-1 short hairpin RNA and interference vector thereof - Google Patents
Sheep Lrh-1 short hairpin RNA and interference vector thereof Download PDFInfo
- Publication number
- CN111334507B CN111334507B CN201911345087.5A CN201911345087A CN111334507B CN 111334507 B CN111334507 B CN 111334507B CN 201911345087 A CN201911345087 A CN 201911345087A CN 111334507 B CN111334507 B CN 111334507B
- Authority
- CN
- China
- Prior art keywords
- lrh
- sheep
- gene
- sequence
- short hairpin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001494479 Pecora Species 0.000 title claims abstract description 41
- 239000013598 vector Substances 0.000 title claims abstract description 41
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 31
- 108091027967 Small hairpin RNA Proteins 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000000137 annealing Methods 0.000 claims abstract description 10
- 108091081021 Sense strand Proteins 0.000 claims description 15
- 230000000692 anti-sense effect Effects 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 230000002452 interceptive effect Effects 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 abstract description 25
- 210000001672 ovary Anatomy 0.000 abstract description 10
- 230000014509 gene expression Effects 0.000 abstract description 9
- 238000003753 real-time PCR Methods 0.000 abstract description 9
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 7
- 238000013461 design Methods 0.000 abstract description 6
- 210000001082 somatic cell Anatomy 0.000 abstract description 6
- 108020004999 messenger RNA Proteins 0.000 abstract description 4
- 239000002299 complementary DNA Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000004925 denaturation Methods 0.000 abstract description 2
- 230000036425 denaturation Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 210000002503 granulosa cell Anatomy 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 101710105538 Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 101150106967 cgaa gene Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011013 endotoxin removal Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- -1 293T cells Substances 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091008637 NR5A Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the field of bioengineering, in particular to sheep Lrh-1 short hairpin RNA and an interference vector thereof. The invention screens out target sequence according to cDNA sequence and design principle of sheep Lrh-1 gene, designs single-stranded oligonucleotide with short hairpin RNA structure according to target sequence, inserts into pENTR/U6 carrier fused with green fluorescence into double-stranded oligonucleotide by denaturation annealing, constructs pENTR/U6-shRNA-GFP interference carrier. The method is characterized in that the gene is transfected into the Hu sheep ovary granular cells, and the real-time fluorescent quantitative PCR method is utilized to detect the mRNA level, so that the Lrh-1-shRNA interference vector can be proved to be capable of effectively inhibiting the expression of the Lrh-1 gene in sheep somatic cells.
Description
Technical Field
The invention relates to the field of bioengineering, in particular to sheep Lrh-1 short hairpin RNA and an interference vector thereof.
Background
Liver receptor homolog-1 (Liver receptor homolog-1, lrh-1) is a mammalian important nuclear receptor and belongs to the 2 nd member of the NR5A subfamily of the superfamily of nuclear receptors, also known as NR5A2, expressed in various tissues of the heart, stomach, lung, brain, gall bladder, exocrine pancreas, salivary gland, intestine, ovary, fat, bladder, testis, adrenal gland, placenta, etc. of animals. Lrh-1 mainly uses a transcription regulating factor to execute its function, and can regulate and control the expression of several proteins in different tissues in different periods so as to affect the development and physiological and biochemical functions of these tissues, and has important functions in the processes of animal embryo development, differentiation, cholesterol metabolism, dynamic balance of bile acid, steroid hormone production, cell transfer and invasion of breast cancer and tissue inflammation reaction, etc.
RNA interference (RNAi) phenomenon is an evolutionarily conserved defense mechanism against transgenic or foreign virus attacks. After double strand RNA (dsRNA) having a sequence homologous to the mRNA of the transcription product of the target gene is introduced into a cell, the mRNA can be specifically degraded, thereby generating a corresponding functional phenotype deletion. The advent of RNA interference technology has made it possible to specifically silence target genes in a specific manner and has become a powerful tool for the treatment of diseases and the study of gene function. At present, RNAi technology opens up a new research field of life sciences, and becomes a research hotspot and leading edge of international life sciences in the 21 st century.
In order to reversely and deeply study the functions of the Lrh-1 gene in sheep cells, interference, silencing, knocking-down or knocking-out of the Lrh-1 gene is required, but no report of knocking-out or knocking-down of the Lrh-1 gene is currently seen.
Disclosure of Invention
In view of the above, the technical problem to be solved by the present invention is to provide sheep Lrh-1 short hairpin RNA and its interference vector, which can produce good knockdown effect on target gene Lrh-1.
The sheep Lrh-1 short hairpin RNA provided by the invention has sense strand 5 '. Fwdarw.3' comprising sequence A, stem-loop sequence 1 and sequence B which are connected in sequence; wherein, the sequence A is reversely complementary with the sequence B; the sequence A is shown in any one of SEQ ID NO 1-3.
The sheep Lrh-1 short hairpin RNA provided by the invention has an antisense strand 5 '. Fwdarw.3' comprising a sequence A, a stem-loop sequence 2 and a sequence B which are sequentially connected; the stem-loop sequence 2 is reverse complementary to the stem-loop sequence 1.
In the sheep Lrh-1 short hairpin RNA provided by the invention, the sequence A in the antisense strand and the sequence B in the sense strand are identical.
In some embodiments, the sequence A is GCACGGACTTACACCTATTGT (SEQ ID NO: 1) and the sequence B is ACAATAGGTGTAAGTCCGTGC (SEQ ID NO: 10);
in some embodiments, the sequence A is GGAATAAGTTCGGGCCCATGT (SEQ ID NO: 2) and the sequence B is ACATGGGCCCGAACTTATTCC (SEQ ID NO: 11);
in some embodiments, the sequence A is GCACAGGAATTGGTGGCAAAG (SEQ ID NO: 3) and the sequence B is CTTTGCCACCAATTCCTGTGC (SEQ ID NO: 12);
the 5' ends of the sense strand and the antisense strand of sheep Lrh-1 short hairpin RNA provided by the invention are connected with connectors, and the connector sequence of the sense strand is CACC; the linker sequence of the antisense strand is AAAA.
In the sheep Lrh-1 short hairpin RNA provided by the invention, the nucleic acid sequence of the stem-loop sequence 1 is CGAA. The nucleic acid sequence of the stem-loop sequence 2 is TTCG.
In some embodiments, the sheep Lrh-1 short hairpin RNA sense strand has a nucleic acid sequence shown in SEQ ID NO. 4 and the antisense strand has a nucleic acid sequence shown in SEQ ID NO. 5;
or the nucleic acid sequence of the sense strand is shown as SEQ ID NO. 6, and the nucleic acid sequence of the antisense strand is shown as SEQ ID NO. 7;
or the nucleic acid sequence of the sense strand is shown as SEQ ID NO. 8, and the nucleic acid sequence of the antisense strand is shown as SEQ ID NO. 9.
The invention also provides ds Oligo synthesized by annealing the sense strand and the antisense strand of the invention.
Specifically, the invention provides ds Oligo formed by annealing the sense strand shown in SEQ ID NO. 4 and the antisense strand shown in SEQ ID NO. 5.
Or dsOligo formed by annealing the sense strand shown in SEQ ID NO. 6 and the antisense strand shown in SEQ ID NO. 7.
Or dsOligo formed by annealing the sense strand shown in SEQ ID NO. 8 and the antisense strand shown in SEQ ID NO. 9.
The invention also provides an interference vector of sheep Lrh-1 gene, which comprises a framework vector and the ds Oligo.
In the embodiment of the invention, the skeleton carrier is pENTR/U6-shRNA-GFP.
In some embodiments, the ds Oligo is inserted into the backbone vector at BamHI and EcoRI sites.
The invention also provides a method for knocking down sheep Lrh-1 gene, which uses the interference vector to transfect a receptor. The transfection adopts a liposome transfection method. The receptor is an animal cell or sheep ovary granulosa cell. In particular 293T cells or Hu sheep ovary granulosa cells.
The invention also provides a cell line with the Lrh-1 gene knocked down, which is obtained by transfecting cells with the interference vector.
A kit for knocking down sheep Lrh-1 gene comprising said short hairpin RNA, said ds Oligo or said interfering vector.
The kit also comprises a transfection reagent.
The invention constructs Lrh-1 short hairpin RNA and constructs an interference vector of Lrh-1 gene, specifically, the invention screens out a target sequence according to cDNA sequence and design principle of sheep Lrh-1 gene, designs single-stranded oligonucleotide with a short hairpin RNA structure according to the target sequence, inserts the single-stranded oligonucleotide into pENTR/U6 vector fused with green fluorescence after denaturation annealing to form pENTR/U6-shRNA-GFP interference vector. The method is characterized in that the gene is transfected into the Hu sheep ovary granular cells, and the real-time fluorescent quantitative PCR method is utilized to detect the mRNA level, so that the Lrh-1-shRNA interference vector can be proved to be capable of effectively inhibiting the expression of the Lrh-1 gene in sheep somatic cells. The interference vector realizes accurate targeting of sheep somatic cell genome, and provides effective experimental research technological basis for further researching the relationship between Lrh-1 gene and other gene functions in sheep somatic cells.
The invention has at least one of the following advantages and effects:
(1) RNA (Lrh-1-shRNA) short hairpin interference vector can be directly used for transfecting sheep cells, specifically inhibiting Lrh-1 gene expression and carrying out RNAi experiments.
(2) The RNA (Lrh-1-shRNA) interference vector is fused with a GFP tag, so that the transfection efficiency can be intuitively monitored under a fluorescence microscope.
(3) The construction of RNA (Lrh-1-shRNA) interference vector provides convenience for the in-depth research of sheep Lrh-1 gene function.
Drawings
FIG. 1 shows shRNA designed according to the present invention;
FIG. 2 shows an interference vector pattern of the present invention;
FIG. 3 shows cell transfection pictures;
FIG. 4 shows the amplification curve (a) and the dissolution curve (b) of GAPDH gene;
FIG. 5 shows the amplification curve (a) and the dissolution curve (b) of the Lrh-1 gene.
Detailed Description
The invention provides sheep Lrh-1 short hairpin RNA and an interference vector thereof, and a person skilled in the art can properly improve the technological parameters by referring to the content of the text. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that the invention can be practiced and practiced with modification and alteration and combination of the methods and applications herein without departing from the spirit and scope of the invention.
The instrument adopted by the invention is a common commercial product and can be purchased in the market.
The invention is further illustrated by the following examples:
EXAMPLE 1Lrh-1 high expression vector construction
1. Materials: pMD18-T vector, oligo DNA, competent cells DH 5. Alpha., playinum PfxDNAnolymerase, platinumTaqDNAPolymerase High Fidelity, quick cut restriction endonuclease: bamH I and EcoR I, T4 DNA ligase.
2. Method of
1) The gene sequence (JN 662490.1) of sheep Lrh-1 in GenBank was analyzed to examine the presence or absence of particularly complex secondary structure and repetitive sequence linkage in the gene.
2) The single-strand oligo was designed and synthesized based on the results of the gene sequence analysis.
3) The synthesized oligo was spliced into a complete gene sequence by PCR.
4) The synthesized sequence is loaded into a pMD18-T vector and transformed into competent cells DH5 alpha.
5) Sequencing to verify if the inserted sequence in the recombinant clone is consistent with the requirement.
6) The mutation points in the gene sequence were repaired by overlap PCR.
7) The constructed pMD18T-Lrh-1 was digested with BamH I and EcoR I to recover an about 1.5kb fragment. The cleavage system is shown in Table 1:
TABLE 1 enzyme digestion system
Plasmid pMD18T-Lrh-1 (150 ng/. Mu.l) | 10μl |
BamH I | 1μl |
EcoR I | 1μl |
10×Q.cut Buffer | 5μl |
ddH 2 O | 33μl |
8) pcDNA3.1 (+) was digested with BamHI and EcoRI and recovered. The cleavage system is shown in Table 2:
TABLE 2 enzyme digestion system
pcDNA3.1 (+) (about 150 ng/. Mu.l) | 6μl |
BamH I | 1μl |
EcoR I | 1μl |
10×Q.cut Buffer | 5μl |
ddH 2 O | 37μl |
9) The digested vector pcDNA3.1 (+) and the fragment Lrh-1 are connected by T4 DNA ligase, competent cells DH5 alpha are transformed, a plurality of clones are selected, a plasmid is prepared by small-scale extraction, and sequencing verification is carried out.
The connection system is shown in Table 3:
table 3 connection system
10×Ligation buffer | 1μl |
Restriction enzyme digestion of DNA fragments | 3.0μl |
Enzyme cutting carrier | 1.0μl |
T4 DNA Ligase(10U/μl) | 0.5μl |
ddH 2 O | 4.5μl |
EXAMPLE 2 interference vector construction
1. Materials: shRNA oligos, linearization vector: pENTR/U6-shRNA-GFP, 10 Xannealing reaction buffer, T4 DNA Ligase, competent cell DH 5. Alpha
2. The method comprises the following steps:
1) Short hairpin 3 shrna oligos were designed based on sheep Lrh-1 gene sequence in GenBank (JN 662490.1) (fig. 1).
2) The CGAA sequence in the middle of the Oligo sense strand and the TTCG sequence in the middle of the antisense strand are short hairpin RNA stem loop structures. The 5 'end of the sense strand template, CACC, and the 5' end of the antisense strand template, AAAA, are designed for the adaptor when ligated to the shuttle plasmid.
3) The synthesized oligos were annealed to form a double strand, and the system was as follows:
TABLE 4 annealing System
Top strand DNA oligo(200μM) | 5μl |
Bottomstrand DNA oligo(200μM) | 5μl |
10×Oligo Annealing Buffer | 2μl |
DNase/RNase-Free Water | 8μl |
Total volume | 20μl |
4) Reacting for 4min at 95 ℃, and then standing for 5-10 min at room temperature;
5) Diluting the reaction product with deionized water by 100 times to make the final concentration of the double-chain oligo mixture be 500nM;
6) 500nM ds oligo mixture was diluted to a final concentration of 10nM with Oligo Annealing Buffer.
7) The system of the ligation vector and ds Oligo is as follows:
table 5 connection system
8) After 2h connection at 16 ℃, the mixture is transformed into competent cells DH5 alpha;
9) The vector (map is shown in FIG. 2): (1) prokaryotic resistance: kan (2) eukaryotic screening resistance: zeocin (3) expressed GFP fluorescent protein (4) ds oligo was inserted at BamH I and EcoR I cleavage sites. (5) The plasmid vector containing the ds oligo shown in the No.1 group was SR51, the plasmid vector containing the ds oligo shown in the No.2 group was SR362, and the plasmid vector containing the ds oligo shown in the No.3 group was SR1159.
10 Sequencing to verify if the interfering vector is correct.
Example 3 evaluation of interference vector knockdown Effect
1. Materials: high expression plasmid: pcDNA3.1 (+) -Lrh-1, shRNA interfering plasmid: SR51, SR362, SR1159 and negative controls, 293T cells, DMEM high sugar medium, fetal bovine serum FBS, transfection reagents: lipofectamine2000, endotoxin removal large extraction kit, reverse transcription kit and SYBR qPCR Mix
2. Method of
1) And preparing the reduction plasmid to be transfected by large extraction (refer to the operation of the endotoxin removal large extraction kit instruction manual).
2) 293T cells were cultured and 6 well plates were spread to achieve a cell density of about 90% the next day.
3) Transfection: the high expression plasmid and the interfering plasmid were co-transfected with lipofectamine2000 and were grouped as follows:
TABLE 6 transfection grouping
Grouping | High-level watchDali plasmid Lrh-1 | Interference carrier | Lipofectamine2000 |
SR51 group | 1μg Lrh-1 | 3μg SR51 | 10μl |
SR362 group | 1μg Lrh-1 | 3μg SR362 | 10μl |
SR1159 group | 1μg Lrh-1 | 3μg SR1159 | 10μl |
NC group | 1μg Lrh-1 | 3μg SR-NC | 10μl |
Blank group | 0 | 0 | 0 |
4) After 48h, the cells were collected, RNA was extracted, reverse transcribed to cDNA, and qPCR was performed to detect the level of expression of the gene of interest Lrh-1. (detailed procedures of reverse transcription and qPCR refer to kit procedure)
TABLE 7 primer information for qPCR
Primer name | Sequence (5'>3’) |
Lrh-F | CTCAAGGTGGATGACCAAATGA(SEQ ID NO:13) |
Lrh-R | TTGCCCAGTAACCAGGAAGAT(SEQ ID NO:14) |
GAPDH-F | AGAAGGCTGGGGCTCATTTG(SEQ ID NO:15) |
GAPDH-R | AGGGGGCCATCCACAGTCTTC(SEQ ID NO:16) |
3. Results
(1) Cell transfection pictures are shown in FIG. 3
(2) qPCR screening results: the amplification and dissolution curves of GAPDH gene are shown in FIG. 4 and Lrh-1 gene in FIG. 5
(3) qPCR data and calculation results are shown in table 8:
table 8qPCR data and calculation results
Sample name | 2 -ΔΔct | Interference efficiency |
SR51 group | 0.641967223 | 35.80% |
SR362 group | 2.110930312 | Without any means for |
SR1159 group | 0.234590083 | 76.54% |
NC group | 1 | 0 |
As can be seen from the above table, SR51 and SR1159 have certain knockdown effect on the target gene Lrh-1, wherein the knockdown efficiency is best SR1159 and is 76.54%, so that the interference plasmid can be selected for downstream experiments.
Example 4 verification of knockdown Effect of interfering vectors in sheep somatic cells
4.1 collecting ovary granulosa cells of sheep (Hu sheep)
Preparing physiological saline at 37-38 ℃, adding gentamicin and green streptomycin, and placing into a thermos bottle for standby. Fresh and complete ovaries of Hu sheep are taken and placed in a vacuum flask and sent to a laboratory within 3 hours.
4.2 collecting and culturing ovary granulosa cells
1) Washing ovary with physiological saline for 5-8 times in ultra clean bench, removing blood and impurities, and stripping ovary membrane. 1mL of DPBS solution containing 1% serum was aspirated first with a 10mL syringe, followed by aspiration of follicular fluid from healthy follicles of 2-5 mm diameter.
2) Centrifuge at 500 Xg for 5min at room temperature, discard supernatant and wash the pellet with PBS 2 times.
3) The supernatant was discarded, and 500. Mu.L of 0.3% hyaluronidase was added to the pellet to digest it for 2min, and the pellet was dispersed by pipetting.
4) Centrifuge at 500 Xg for 3min at room temperature, discard supernatant and wash the pellet 2 times with PBS.
5) The cells were resuspended in a T75 cell culture flask at 37℃in a 5% carbon dioxide incubator by centrifugation at 500 Xg at room temperature for 3min, the supernatant was discarded, and the cells were incubated in a pre-warmed 10mL cell culture medium.
4.3 transfection of the interference vector Lrh-1-shRNA into granulosa cells
Plasmid SR1159 with relatively optimal transfection effect is selected for transfection of Hu sheep granulosa cells, and the experimental operation method is the same as that of example 3, and the experiment is repeated three times and is respectively marked as Lrh-1 knockout 1, lrh-1 knockout 2 and Lrh-1 knockout 3.
4.4 detection of Lrh-1mRNA expression in granulosa cells
And (3) taking the Lrh-1 knockout 1-3 cells prepared in the step (4.3) as a sample to be detected, and repeatedly detecting each group of cells. The detection was performed using GAPDH as a control. Control cells were arranged in three groups, each of which was tested in triplicate.
4.4.1 RNA extraction from granulosa cells
Pressing the buttonPlus RNA Purification Kit (Invitrogen cat# 12183-555) the kit requires handling and then storage at-80℃for use.
4.4.2 reverse transcription experiments
(1) Reagent: superScript TM III First-Strand Synthesis SuperMix for qRT-PCR
(Invitrogen cat# 11752-050)
(2) Instrument: constant temperature metal bath (domestic)
(3) Operating procedure
Table 9:1st-Strand cDNA Synthesis reaction System and conditions
4.4.3real-Time PCR detection
(1) Reagent: powerGreen PCRMaster Mix (Roche goods number 4913914001)
(2) Instrument: quantum multiple real-time fluorescent quantitative PCR instrument (American life technologies company)
(3) Experimental procedure
(1) Fluorescent quantitative PCR primer design and synthesis
Quantitative PCR Primer design was performed using Primer Premier 6.0 and Beacon designer 7.8 software, and then synthesis was performed with the following Primer sequences:
table 10: real-Time PCR Primers and Conditions
(2) Real-Time PCR amplification system and reaction conditions
Table 11: quantitative PCR reaction system and conditions
(3) Real-Time PCR gene expression difference statistical analysis
Each sample was repeated three times, and the relative expression level of each gene was expressed at 2 (Ct Reference gene -Ct Target gene ) Statistical analysis was performed.
4.4.4Lrh-1 quantitative results
TABLE 12 quantitative results
Experimental results show that the constructed Lrh-1-shRNA interference vector can effectively knock down the expression of the Lrh-1 gene in the Hu sheep somatic cells.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Sequence listing
<110> Jiangsu agricultural and grazing science and technology academy of professions
<120> sheep Lrh-1 short hairpin RNA and interference vector thereof
<130> MP1934713
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 1
gcacggactt acacctattg t 21
<210> 2
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 2
ggaataagtt cgggcccatg t 21
<210> 3
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 3
gcacaggaat tggtggcaaa g 21
<210> 4
<211> 50
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 4
caccgcacgg acttacacct attgtcgaaa caataggtgt aagtccgtgc 50
<210> 5
<211> 50
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 5
aaaagcacgg acttacacct attgtttcga caataggtgt aagtccgtgc 50
<210> 6
<211> 50
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 6
caccggaata agttcgggcc catgtcgaaa catgggcccg aacttattcc 50
<210> 7
<211> 50
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 7
aaaaggaata agttcgggcc catgtttcga catgggcccg aacttattcc 50
<210> 8
<211> 50
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 8
caccgcacag gaattggtgg caaagcgaac tttgccacca attcctgtgc 50
<210> 9
<211> 50
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 9
aaaagcacag gaattggtgg caaagttcgc tttgccacca attcctgtgc 50
<210> 10
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 10
acaataggtg taagtccgtg c 21
<210> 11
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 11
acatgggccc gaacttattc c 21
<210> 12
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 12
ctttgccacc aattcctgtg c 21
<210> 13
<211> 22
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 13
ctcaaggtgg atgaccaaat ga 22
<210> 14
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 14
ttgcccagta accaggaaga t 21
<210> 15
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 15
agaaggctgg ggctcatttg 20
<210> 16
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 16
agggggccat ccacagtctt c 21
Claims (6)
1. Sheep Lrh-1 short hairpin RNA,
the nucleic acid sequence of the sense strand is shown as SEQ ID NO. 8,
the nucleic acid sequence of the antisense strand is shown in SEQ ID NO. 9.
2. A ds Oligo synthesized by annealing the sense strand and the antisense strand of the short hairpin RNA of claim 1.
3. An interfering vector of sheep Lrh-1 gene, comprising a backbone vector and the ds Oligo of claim 2.
4. The interfering vector of claim 3, wherein the backbone vector is pENTR/U6-shRNA-GFP.
5. A method of knocking down sheep Lrh-1 gene, wherein the interfering vector of claim 3 or 4 is used to transfect a receptor.
6. A kit for knocking down sheep Lrh-1 gene comprising the short hairpin RNA of claim 1, the ds Oligo of claim 2, or the interfering vector of claim 3 or 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911345087.5A CN111334507B (en) | 2019-12-24 | 2019-12-24 | Sheep Lrh-1 short hairpin RNA and interference vector thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911345087.5A CN111334507B (en) | 2019-12-24 | 2019-12-24 | Sheep Lrh-1 short hairpin RNA and interference vector thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111334507A CN111334507A (en) | 2020-06-26 |
CN111334507B true CN111334507B (en) | 2024-01-30 |
Family
ID=71181388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911345087.5A Active CN111334507B (en) | 2019-12-24 | 2019-12-24 | Sheep Lrh-1 short hairpin RNA and interference vector thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111334507B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003201A2 (en) * | 2002-07-01 | 2004-01-08 | Pharmacia Corporation | Antisense modulation of lrh1 expression |
CN101139615A (en) * | 2007-08-06 | 2008-03-12 | 湖北大学 | Method for quickly and highly effectively constructing mammal cell RNA interference carrier and its checking carrier |
CN102321669A (en) * | 2011-08-08 | 2012-01-18 | 中国农业科学院北京畜牧兽医研究所 | Novel shRNA (short hairpin ribonucleic acid) for promoting animal growth and application thereof |
CN102433337A (en) * | 2011-11-22 | 2012-05-02 | 新疆维吾尔自治区畜牧科学院中国-澳大利亚绵羊育种科学研究中心 | Seven synthesized shRNA (short hairpin ribonucleic acid) molecules for inhibiting expression of BMPR-1B (bone morphogenetic protein receptor-1B) genes |
-
2019
- 2019-12-24 CN CN201911345087.5A patent/CN111334507B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003201A2 (en) * | 2002-07-01 | 2004-01-08 | Pharmacia Corporation | Antisense modulation of lrh1 expression |
CN101139615A (en) * | 2007-08-06 | 2008-03-12 | 湖北大学 | Method for quickly and highly effectively constructing mammal cell RNA interference carrier and its checking carrier |
CN102321669A (en) * | 2011-08-08 | 2012-01-18 | 中国农业科学院北京畜牧兽医研究所 | Novel shRNA (short hairpin ribonucleic acid) for promoting animal growth and application thereof |
CN102433337A (en) * | 2011-11-22 | 2012-05-02 | 新疆维吾尔自治区畜牧科学院中国-澳大利亚绵羊育种科学研究中心 | Seven synthesized shRNA (short hairpin ribonucleic acid) molecules for inhibiting expression of BMPR-1B (bone morphogenetic protein receptor-1B) genes |
Non-Patent Citations (3)
Title |
---|
张瑞杰 ; 苗向阳 ; .绵羊抑制素shRNA慢病毒干扰载体的构建与鉴定.华北农学报.2011,(03),全文. * |
王利红 ; 张伟 ; .湖羊HPG轴组织中LRH-1表达定位分析.中国畜牧杂志.2017,(11),全文. * |
王利红 ; 高勤学 ; 张伟 ; 王锋 ; .湖羊Lrh-1基因cDNA序列及组织表达谱分析.畜牧兽医学报.2012,(09),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN111334507A (en) | 2020-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hosono et al. | Oncogenic role of THOR, a conserved cancer/testis long non-coding RNA | |
Pang et al. | Genome-wide identification of long noncoding RNAs in CD8+ T cells | |
Geurts et al. | Generation of gene-specific mutated rats using zinc-finger nucleases | |
Zhang et al. | Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats | |
Pan et al. | MicroRNA-574 suppresses oocyte maturation via targeting hyaluronan synthase 2 in porcine cumulus cells | |
WO2019227640A1 (en) | Reagent and method for repairing fbn1t7498c mutation using base editing | |
CN109182562B (en) | miRNA apla-mir-25-42 related to follicular development of laying ducks as well as detection primer, inhibitor and application thereof | |
Kropp et al. | mRNA fragments in in vitro culture media are associated with bovine preimplantation embryonic development | |
CN109402118B (en) | miRNA apla-mir-145-4 related to follicular development of laying ducks as well as detection primer, inhibitor and application thereof | |
CN111334507B (en) | Sheep Lrh-1 short hairpin RNA and interference vector thereof | |
Cuthbert et al. | Dynamics of small non-coding RNAs in bovine scNT embryos through the maternal-to-embryonic transition | |
Zhang et al. | Method to enhance transfection efficiency of cell lines and placental fibroblasts | |
CN106544360B (en) | A method of terminating the transcription of lncRNA diallele | |
CN109402244B (en) | Sex identification method for mammalian embryo | |
CN106244593A (en) | A kind of microRNA regulating Cornu Cervi Pantotrichum young pilose antler skin fast-growth and application thereof | |
CA3096274A1 (en) | Compositions and methods for somatic cell reprogramming and modulating imprinting | |
Luo et al. | MicroRNA-101 regulates oocyte maturation in vitro via targeting HAS2 in porcine cumulus cells | |
Gao et al. | Aal-circRNA-407 regulates ovarian development of Aedes albopictus, a major arbovirus vector, via the miR-9a-5p/Foxl axis | |
CN115279900A (en) | Optimized methods for cleaving a target sequence | |
Xie et al. | Precise genome editing of the Kozak sequence enables bidirectional and quantitative modulation of protein translation to anticipated levels without affecting transcription | |
CN107201365B (en) | A kind of sgRNA sequences of specific knockdown dihydrofolate reductase gene and its application | |
CN109082426A (en) | The zebra fish cip2a gene mutation body and its construction method constructed using CRISPR-Cas9 | |
CN102965371A (en) | SiRNA inhibiting BMP15 gene expression and application thereof | |
CN115161392B (en) | Application of TMEM144 in preparation of tumor drugs | |
Sagar et al. | Prediction and in vitro silencing of two lipid biosynthetic genes viz. SCD and SREBP1 in chicken using RNA interference |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |